OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$6.58 USD
-0.05 (-0.75%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.58 0.00 (0.00%) 6:42 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.58 USD
-0.05 (-0.75%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $6.58 0.00 (0.00%) 6:42 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Misses Q3 Earnings Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -30.77% and 8.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 42.86% and 10.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OptimizeRx Corp. (OPRX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 200.00% and 8.79%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Mar 17, 2021
by Zacks Equity Research
Companies in the news are: JBL, CNF, OPRX, MRNA
OptimizeRx Corp. (OPRX) Soars 12%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 6.67% and 2.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx's (OPRX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in OptimizeRx (OPRX).
OptimizeRx (OPRX) Looks Good: Stock Adds 9.5% in Session
by Zacks Equity Research
OptimizeRx (OPRX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
OptimizeRx's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in OptimizeRx.
Zacks.com featured highlights include: Digital Turbine, Perion, Controladora Vuela, OptimizeRx and Eldorado Gold
by Zacks Equity Research
Zacks.com featured highlights include: Digital Turbine, Perion, Controladora Vuela, OptimizeRx and Eldorado Gold
5 Breakout Stocks for Explosive Returns
by Swarup Gupta
This method involved zeroing in on those stocks whose prices are varying within a narrow band.
Has OptimizeRx (OPRX) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (OPRX) Outperforming Other Computer and Technology Stocks This Year?
OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.
OptimizeRx (OPRX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
OptimizeRx (OPRX) closed the most recent trading day at $15.09, moving +0.8% from the previous trading session.
OptimizeRx (OPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx (OPRX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, OptimizeRx (OPRX) closed at $15.11, marking a -0.66% move from the previous day.
OptimizeRx (OPRX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, OptimizeRx (OPRX) closed at $15, marking a -0.73% move from the previous day.
Top Ranked Growth Stocks to Buy for June 28th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 28th